Skip to main content
. Author manuscript; available in PMC: 2025 Dec 21.
Published in final edited form as: Immunity. 2025 Oct 2;58(10):2472–2488.e9. doi: 10.1016/j.immuni.2025.09.008

Figure 2. Blimp1 directly antagonizes Tcf7 expression in CD8+ T cells in vitro.

Figure 2.

(A and B) (A) TCF-1 protein levels and (B) TCF-1+ cell frequencies in co-cultured WT (filled columns) and Tcf7Δ+22kb mutant (open columns) CD8+ T cells were stimulated for 3 days with anti-CD3/28 with either 100 U/mL IL-2 or 10 ng/mL IL-12 and subsequently rested for 3 days in 100 U/mL IL-2 or 10 ng/mL IL-15. Data from three experiments are shown with mean ± SD. Two-way ANOVA and Sidak’s multiple comparisons test.

(C) TCF-1 levels in co-cultured WT and Prdm1F/F Cd8cre CD8+ T cells on day 6 of culture in the indicated conditions. Representative of a technical duplicate from one experiment.

(D) TCF-1 expression in WT and Tcf7Δ+22kb T cells electroporated with Cd19 or Tcf7+17kb targeting Cas9-sgRNA complexes and cultured 3 days with anti-CD3/28 with 10 ng/mL IL-12 followed by resting 3 days in 100 U/mL IL-2. Data are representative of two experiments. See also Figure S1.